SecBot SecBot
SECBOTREPLAY Home › Report › ZYME

ZYME · Zymeworks Inc

Zymeworks Inc. · PRESS-RELEASE filed Jun 29, 2026 at 06:00 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Jun 29, 2026 at 06:00 ET

Zymeworks Inc. (ZYME) announced an agreement to acquire Theravance Biopharma (TBPH) for $17.00 per share, or approximately $929 million in total cash consideration. The acquisition adds YUPELRI® (revefenacin), the first and only approved nebulized LAMA for COPD maintenance treatment, which generated ~$60 million in annualized cash flow. The deal is financed via a $350 million non-recourse note from OMERS Life Sciences, $219 million of Zymeworks' cash, and Theravance's ~$360 million expected net cash, with an expected $100 million TRELEGY milestone in Q1 2027 reducing net investment. The transaction is expected to be accretive to earnings and cash flow upon closing in H2 2026.

  • Total transaction value: ~$929 million cash consideration at $17.00 per share.
  • YUPELRI® net sales: $266.6M in 2025 (12% YoY growth), $62.4M in Q1 2026 (7% growth).
  • Financing: $350M non-recourse note from OMERS Life Sciences; $219M Zymeworks cash; Theravance expected net cash ~$360M.
  • Expected $100M TRELEGY milestone from Royalty Pharma in Q1 2027.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access